For a better future SCM Lifescience will do its best
SCM Life Science completed the initiation meeting for phase 2 clinical trials of atopic treatments at four local hospitals… Expanding the recruitment of atopic dermatitis patients outside the Seoul me tropolitan area

SCM Life Science (SCM Life Science, Kosdaq 298060, CEO Lee Byung-gun), a development company specializing in cell therapy, is targeting ▲ Kyungpook National University Hospital ▲ Pusan National University Hospital ▲ Chonnam National University Hospital ▲ Chungnam National University Hospital. 


The people in charge of the clinical trial for phase 2 clinical trials of ADT2002 at a local hospital this time is Professor Jang Yong-hyun of Kyungpook National University Hospital, Professor Ko Hyun-chang of Pusan National University Yangsan Hospital, Professor Na Chan-ho of Chosun University Hospital, and Professor Seo Young-joon of Chungnam National University Hospital. All professors are dermatologists. If you are interested in clinical participation, you can visit the hospital's outpatient clinic and receive information through the doctor in charge.


The clinical initiation meeting is the last step in confirming the overall contents necessary for clinical trials prior to recruiting clinical trial subjects, and the hospital can complete the clinical initiation meeting to discuss clinical participation with patients. The four hospitals that completed the opening meeting will actively work to secure local patients. Patients with moderate or higher atopic dermatitis can participate in clinical trials.


SCM Life Science has been undergoing phase 2 clinical trials at 11 hospitals nationwide, starting with its first administration in February this year, and in June, the above four hospitals were added as clinical trial institutions. By completing the clinical trial initiation meeting for four hospitals this time, SCM Life Science expects to proceed faster to secure phase 2 clinical patients for ADT2002.


SCM Life Science announced the results of a successful phase 1 clinical trial for ADT2002 in December. In phase 1 clinical trials, 13 out of 19 patients (68%) reported an improvement in the EASI score, which evaluates the severity of atopic dermatitis by more than 50%. In addition, 12 out of 13 patients (92%) with improved EASI scores by 50% or more have been observed to maintain long-term efficacy for more than 6 months.


An official from SCM Life Science said, "All preparations for clinical progress have been completed in the newly added four local hospitals,", "We plan to speed up phase 2 clinical trials of ADT2002 by recruiting clinical patients from various regions."